MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2

Upregulation of miR-181b-5p enhances chemosensitivity of glioma cells to temozolomide (TMZ).

• miR-181b-5p is less expressed in human gliomas and functions as a tumor-suppressive microRNA.
• In glioma cells U87MG and U251, miR-181b-5p increases sensitivity to TMZ, leading to reduced cell proliferation, migration, and invasion.
• Combination treatment of miR-181b-5p and TMZ promotes apoptosis and cell cycle arrest more effectively than either treatment alone.
• miR-181b-5p directly targets the Bcl-2 protein, resulting in its reduced expression.
• In vivo experiments suggest that miR-181b-5p enhances the tumor-suppressive effects of TMZ.

AI simplified